Cullinan Therapeutics rebranded from oncology to immunology+oncology, focusing on CD19 TCEs for autoimmune diseases. Check ...

Global demand for anatomic pathology is accelerating, driven by clinical complexity, molecular integration, AI adoption, ...

A landmark migraine study presented at AAN 2025 identified 778 new genetic variants linked to migraine across ancestries in ...

The European Commission approves AstraZeneca's Enhertu for a new breast cancer indication while also expanding Imfinzi label ...

EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer ...

Drs Ursula A. Matulonis and Gini F. Fleming discuss the state of endometrial cancer, the role of immunotherapy, and priorities for research in this field.

The FDA cleared the firm this week to begin a Phase I study of ALX2004 in EGFR-expressing solid tumors, which could start in a few months.

Most EGFR-mutated NSCLCs show some level of HER3 expression, but for now there are no HER3 directed therapies approved for NSCLC or any other form of cancer. The trial – called HERTHENA-Lung02 ...

With an arsenal of antibody assets based on IgE, IgA, and IgG, the newly combined company has opportunities across cancer indications.

A phase 3 clinical trial of ociperlimab for advanced non-small cell lung cancer has been halted after early results showed it ...

A 2024 review of studies details evidence for its use in wound healing, maintaining hydration, and treating conditions that include acne and psoriasis. The anti-aging and anti-inflammatory properties ...

Treatment resistance and relapse in the most common type of lung cancer can be traced to a protein called agrin, according to ...